SCHERING-PLOUGH’s LEUCOMAX (GM-CSF) CMV INDICATION COULD BE APPROVED BY END OF YEAR, COMPANY INDICATES; CEDAX APPROVAL UNLIKELY BEFORE MID-1994

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".